Diabetology has identified classes of compounds that appear to facilitate insulin absorption in the small intestine adequately to meet clinical and commercial objectives, and that are already used for completely different purposes as excipients in pharmaceutical formulations
Use of such agents in its third-generation Axcess™ delivery technology thereby obviates one major aspect of regulatory risk - the risk of toxicity with novel facilitator agents or carriers - while also potentially reducing development timelines by eliminating the need for certain preparatory toxicology studies
Use of such agents for oral peptide delivery is novel and, the Company believes, patentable; the Company has exclusive licenses in the field of diabetes to a series of patent applications covering Axcess delivery technology
Potentially improving glycaemic control through optimal physiological delivery route
Also, potentially improving compliance
Finally, the Company believes that its readily available facilitator compounds may endow it with advantages over competing oral insulin delivery systems that seek to employ new chemical entities
Primary Indication
Treatment of Type 1 diabetes mellitus
Stage of Development
Phase II
As an alternative to inhaled/injected insulin, Capsulin™ IR will effectively deliver insulin orally to those with Type 1 diabetes and late stage Type 2, where they are dependent on insulin supplementation
Reducing the need for injections and/or inhaler equipment
Potentially improving glycaemic control through optimal physiological delivery route
